ACL — Australian Clinical Labs Cashflow Statement
0.000.00%
- AU$497.25m
- AU$798.89m
- AU$697.07m
- 74
- 72
- 46
- 69
Annual cashflow statement for Australian Clinical Labs, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Changes in Working Capital | 0.038 | 0.037 | 0.075 | 0.045 | 0.182 |
Other Operating Cash Flow | |||||
Cash from Operating Activities | 1.11 | 102 | 154 | 284 | 144 |
Capital Expenditures | -14.4 | -9.38 | -9.51 | -21.3 | -6.93 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 0.988 | -0.577 | 3.43 | -50.8 | -5.25 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -13.4 | -9.96 | -6.08 | -72 | -12.2 |
Financing Cash Flow Items | — | — | -216 | -0.061 | 0 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 9.52 | -60.9 | -147 | -221 | -138 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -2.74 | 30.7 | 0.384 | -8.86 | -6.42 |